Terms: = Ovarian cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
165 results:
1. Effect of myc and PARP Inhibitors in ovarian cancer Using an
Morea A; Saravi S; Sisu C; Hall M; Tosi S; Karteris E; Storlazzi CT
Anticancer Res; 2024 May; 44(5):1817-1827. PubMed ID: 38677725
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
3. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
4. Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level.
Perkiö A; Pradhan B; Genc F; Pirttikoski A; Pikkusaari S; Erkan EP; Falco MM; Huhtinen K; Narva S; Hynninen J; Kauppi L; Vähärautio A
Sci Rep; 2024 Feb; 14(1):4322. PubMed ID: 38383551
[TBL] [Abstract] [Full Text] [Related]
5. LINC00629, a HOXB4-downregulated long noncoding RNA, inhibits glycolysis and ovarian cancer progression by destabilizing c-myc.
Liu J; Zhu Y; Wang H; Han C; Wang Y; Tang R
Cancer Sci; 2024 Mar; 115(3):804-819. PubMed ID: 38182548
[TBL] [Abstract] [Full Text] [Related]
6. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
7. Epigallocatechin gallate inhibits ovarian cancer cell growth and induces cell apoptosis via activation of FOXO3A.
Zhang Z; Zhang Q; Yu Y; Su S
In Vitro Cell Dev Biol Anim; 2023 Dec; 59(10):739-746. PubMed ID: 38038884
[TBL] [Abstract] [Full Text] [Related]
8. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
9. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
[TBL] [Abstract] [Full Text] [Related]
10. myc is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J; Yemelyanenko J; Chao X; Klarenbeek S; Opdam M; Malka Y; Hoekman L; Kruger D; Bleijerveld O; Brambillasca CS; Sprengers J; Siteur B; Annunziato S; van Haren MJ; Martin NI; van de Ven M; Peters D; Agami R; Linn SC; Boven E; Altelaar M; Jonkers J; Zingg D; Wessels LFA
J Exp Med; 2023 Nov; 220(11):. PubMed ID: 37642941
[TBL] [Abstract] [Full Text] [Related]
11. HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.
Di Agostino S; Canu V; Donzelli S; Pulito C; Sacconi A; Ganci F; Valenti F; Goeman F; Scalera S; Rollo F; Bagnato A; Diodoro MG; Vizza E; Carosi M; Rufini B; Federici O; Giofrè M; Carboni F; Muti P; Ciliberto G; Strano S; Valle M; Blandino G
Cell Death Dis; 2023 Aug; 14(8):535. PubMed ID: 37598177
[TBL] [Abstract] [Full Text] [Related]
12. HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers.
Yan M; Cao H; Tao K; Xiao B; Chu Y; Ma D; Huang X; Han Y; Ji T
Gene; 2023 Nov; 885():147704. PubMed ID: 37572797
[TBL] [Abstract] [Full Text] [Related]
13. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
14. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract] [Full Text] [Related]
15. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
16. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on ovarian cancer Predicted by Network-Based Pharmacology.
Liu Y; Guo Z; Lang F; Li J; Jiang J
Appl Biochem Biotechnol; 2023 Nov; 195(11):6994-7020. PubMed ID: 36976504
[TBL] [Abstract] [Full Text] [Related]
17. SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma.
Lee YM; Chen YH; Ou DL; Hsu CL; Liu JH; Ko JY; Hu MC; Tan CT
J Pathol; 2023 Apr; 259(4):428-440. PubMed ID: 36641765
[TBL] [Abstract] [Full Text] [Related]
18. Targeting myc Regulation with Polypurine Reverse Hoogsteen Oligonucleotides.
Valiuska S; Psaras AM; Noé V; Brooks TA; Ciudad CJ
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613820
[TBL] [Abstract] [Full Text] [Related]
19. Effects of the exercise-inducible myokine irisin on proliferation and malignant properties of ovarian cancer cells through the HIF-1 α signaling pathway.
Alizadeh Zarei M; Seyed Hosseini E; Haddad Kashani H; Ahmad E; Nikzad H
Sci Rep; 2023 Jan; 13(1):170. PubMed ID: 36599894
[TBL] [Abstract] [Full Text] [Related]
20. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in myc-high high-grade serous ovarian carcinoma.
Raninga PV; He Y; Datta KK; Lu X; Maheshwari UR; Venkat P; Mayoh C; Gowda H; Kalimutho M; Hooper JD; Khanna KK
Mol Ther; 2023 Mar; 31(3):729-743. PubMed ID: 36560881
[TBL] [Abstract] [Full Text] [Related]
[Next]
